Methyltransferase inhibitors for treatment of COVID19
ERC (European Research Council)HORIZON-ERC-POCID: 101069369
EC Contribution
€1,500
Consortium Size
1 orgs
Start Year
2022
▶Summary
Our IP secured drug DZNep is effective in treating SARS-CoV-2 infections in preclinical disease models and uniquely suppresses virus growth, triggers the innate immunity and facilitates tissue regeneration. The ERC-PoC will enable the transition from preclinical to clinical research.